Apellis Pharmaceuticals, Inc. (APLS) P/E Ratio History
ExpensiveTrading at 227.9x vs 5Y avg 83.5x · 100th percentile · Material premium to history · Data 2025–2026
Loading P/E history...
P/E Ratio Analysis
As of October 4, 2026, Apellis Pharmaceuticals, Inc. (APLS) trades at a price-to-earnings ratio of 227.9x, with a stock price of $41.03 and trailing twelve-month earnings per share of $1.06.
The current P/E is 173% above its 5-year average of 83.5x. Over the past five years, APLS's P/E has ranged from a low of 38.0x to a high of 147.8x, placing the current valuation at the 100th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.2x, APLS trades at a 884% premium to its sector peers. The sector includes 225 companies with P/E ratios ranging from 0.0x to 190.0x.
Relative to the broader market, APLS commands a significant premium over the S&P 500 median P/E of 24.5x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our APLS DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
APLS Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
APLS P/E vs Peers
Immunology and Inflammation Therapies peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 6.2Lowest | 0.60 | +817%Best | |
| $76B | 17.7 | 2.80 | +8% | |
| $32B | 24.9 | - | -21% | |
| $5B | 15.4 | 0.39Best | -5% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
APLS Historical P/E Data (2025–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $40.23 | $1.06 | 38.0x | -55% |
| FY2025 Q4 | Dec 31 2025 | $25.12 | $0.17 | 147.8x | +77% |
| FY2025 Q3 | - | $22.63 | $0.35 | 64.7x | -23% |
Average P/E for displayed period: 83.5x
APLS Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
1+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
APLS — Frequently Asked Questions
Quick answers to the most common questions about buying APLS stock.
What is APLS's P/E ratio?
Apellis Pharmaceuticals, Inc. (APLS) trailing twelve-month P/E ratio is 227.9x, based on TTM diluted EPS of $1.06. The 5-year average P/E is 83.5x and the historical range spans 38.0x to 147.8x.
Is APLS stock overvalued or undervalued?
APLS trades at 227.9x P/E, above its 5-year average of 83.5x. The 100th percentile ranking within the 38.0x–147.8x historical range indicates a premium to historical valuation.
Is APLS stock expensive?
Yes, APLS is expensive relative to its own history. The current P/E of 227.9x is above the 5-year average of 83.5x and also above the Healthcare sector median of 23.2x. The stock sits at the 100th percentile of its 5-year valuation range.
What is APLS's historical P/E range?
Over the past 5 years, APLS's P/E ratio has ranged from 38.0x to 147.8x, with a median of 64.7x and an average of 83.5x. The current P/E of 227.9x places the stock at the 100th percentile of this range. Full historical data spans 2025–2026.
How does APLS's P/E compare to the S&P 500?
APLS trades at 227.9x P/E versus the S&P 500 median of 24.5x. The 830% premium to the market typically reflects higher expected earnings growth or quality.
How does APLS's valuation compare to Healthcare peers?
Apellis Pharmaceuticals, Inc. P/E of 227.9x compares to the Healthcare sector median of 23.2x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is APLS's PEG ratio?
APLS PEG ratio is N/A, based on a P/E of 227.9x and EPS growth of 111.3%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is APLS's earnings yield?
APLS earnings yield is 0.44%, the inverse of its 227.9x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.